Cosmo pharmaceuticals
Key Financial Data

Key Financial Data

EUR 1,000202220212020201920182017
Income statements
Revenues102,08965,07460,94962,49565,61767,242
Cost of sales(40,488)(32,977)(27,617)(25,053)(22,058)(21,988)
Gross Profit61,60132,09733,33237,44243,559 45,254
Other income1,8968195,848753886470
R&D costs(15,525)(11,357)(13,597)(15,160)(10,428)(9,049)
SG&A costs(19,915)(10,458)(18,678)(35,342)(50,638)(46,279)
Net operating expenses(33,544)(20,996)(26,427)(49,749)(60,180)(54,858)
Operating profit28,05711,1016,905(12,307)(16,621)(9,604)
Net result from disposal of controlling interests
Share of result of associates17,753(4,941)(5,064)(5,453)(5,892)
Net financial income / (expenses)(3,584)(4,292)(8,895)(3,933)4,615(16,936)
Loss from remeasurement of previously held investment in associate(559)
Profit / (loss) before taxes24,47324,003(6,931)(21,304)(17,459)(32,432)
Profit / (loss) after taxes for the period17,50521,673(7,901)(24,494)(18,057)(32,447)
Statement of financial position
Non-current assets453,495529,713343,293282,795251,519300,688
Cash and cash equivalents185,825198,560185,937110,387210,689144,944
Other current assets120,27277,28966,931191,978163,47852,362
Liabilities295,804292,884196,036191,427180,83227,857
Equity attributable to owners of the Company456,927505,276400,125393,733443,760470,117
Non-controlling interests6,8617,4021,094
Equity ratio (in %)61.1%63.6%67.1%67.0%71.0%94.0%
Shares
Weighted average number of shares16,425,39516,842,05414,471,06414,633,29915,005,41414,809,753
Earnings per share (in EUR)1.0491.287(0.546)(1.669)(1.200)(2.191)

View Full Key Financial Data